224 related articles for article (PubMed ID: 2885345)
1. Early phase II clinical trial of remoxipride in treatment of schizophrenia with measurements of prolactin and neuroleptic activity.
Chouinard G
J Clin Psychopharmacol; 1987 Jun; 7(3):159-64. PubMed ID: 2885345
[TBL] [Abstract][Full Text] [Related]
2. Remoxipride in schizophrenia: effects on plasma prolactin.
Chouinard G; Turnier L; Kallai-Sanfacon MA
Prog Neuropsychopharmacol Biol Psychiatry; 1985; 9(5-6):599-603. PubMed ID: 2868493
[TBL] [Abstract][Full Text] [Related]
3. An early phase II clinical trial of remoxipride in schizophrenia with measurement of plasma neuroleptic activity.
Chouinard G; Turnier L
Psychopharmacol Bull; 1986; 22(1):267-71. PubMed ID: 2873615
[No Abstract] [Full Text] [Related]
4. [Remoxipride, a selective antagonist of dopamine D2 receptors, in the treatment of delusional psychoses].
Lewander T; Westerberg SE; Ogren SO; Von Bahr C; Köhler C
Encephale; 1990; 16(2):153-7. PubMed ID: 1972054
[TBL] [Abstract][Full Text] [Related]
5. A double-blind comparative multicentre study of controlled-release remoxipride, immediate-release remoxipride and haloperidol in schizophrenia.
Hebenstreit GF; Laux G; Schubert H; Beckmann H; Amman J; Bunse J; Eikmeier G; Geretsegger C; Kanitz RD; Kanzow WT
Pharmacopsychiatry; 1991 Sep; 24(5):153-8. PubMed ID: 1685572
[TBL] [Abstract][Full Text] [Related]
6. Atypical neuroleptics in acute schizophrenia: a double-blind comparative study of remoxipride and haloperidol.
den Boer JA; Westenberg HG
Psychopharmacol Bull; 1990; 26(1):99-107. PubMed ID: 1973547
[TBL] [Abstract][Full Text] [Related]
7. A Canadian multicenter placebo-controlled study of fixed doses of risperidone and haloperidol in the treatment of chronic schizophrenic patients.
Chouinard G; Jones B; Remington G; Bloom D; Addington D; MacEwan GW; Labelle A; Beauclair L; Arnott W
J Clin Psychopharmacol; 1993 Feb; 13(1):25-40. PubMed ID: 7683702
[TBL] [Abstract][Full Text] [Related]
8. Plasma concentrations of remoxipride and haloperidol in relation to prolactin and short-term therapeutic outcome in schizophrenic patients.
Lahdelma RL; Appelberg B; Kuoppasalmi K; Katila H; Rimón R
Eur Neuropsychopharmacol; 1991 Dec; 1(4):535-40. PubMed ID: 1688013
[TBL] [Abstract][Full Text] [Related]
9. Remoxipride and haloperidol in schizophrenia: a double-blind multicentre study.
Ahlfors UG; Rimön R; Appelberg B; Hagert U; Harma P; Katila H; Mahlanen A; Mehtonen OP; Naukkarinen H; Outakoski J
Acta Psychiatr Scand Suppl; 1990; 358():99-103. PubMed ID: 1978501
[TBL] [Abstract][Full Text] [Related]
10. Remoxipride and haloperidol in the acute phase of schizophrenia: a double-blind comparison.
Deo R; Soni S; Rastogi SC; Levine S; Plant I; Edwards JG; Mitchell M; Chanas A
Acta Psychiatr Scand Suppl; 1990; 358():120-4. PubMed ID: 1978470
[TBL] [Abstract][Full Text] [Related]
11. Tiapride in the treatment of tardive dyskinesia: a clinical and biochemical study.
Perényi A; Arató M; Bagdy G; Frecska E; Szücs R
J Clin Psychiatry; 1985 Jun; 46(6):229-31. PubMed ID: 2860098
[TBL] [Abstract][Full Text] [Related]
12. A dose-finding study with remoxipride in the acute treatment of schizophrenic patients.
Lapierre YD; Ancill R; Awad G; Bakish D; Beaudry P; Bloom D; Chandrasena R; Das M; Durand C; Elliott D
J Psychiatry Neurosci; 1992 Oct; 17(4):134-45. PubMed ID: 1450186
[TBL] [Abstract][Full Text] [Related]
13. Atypical antipsychotics: mechanism of action.
Seeman P
Can J Psychiatry; 2002 Feb; 47(1):27-38. PubMed ID: 11873706
[TBL] [Abstract][Full Text] [Related]
14. Beneficial antipsychotic effects of allopurinol as add-on therapy for schizophrenia: a double blind, randomized and placebo controlled trial.
Akhondzadeh S; Safarcherati A; Amini H
Prog Neuropsychopharmacol Biol Psychiatry; 2005 Feb; 29(2):253-9. PubMed ID: 15694232
[TBL] [Abstract][Full Text] [Related]
15. Long term treatment of tardive dyskinesia.
Jus A; Jus K; Fontaine P
J Clin Psychiatry; 1979 Feb; 40(2):72-7. PubMed ID: 33156
[TBL] [Abstract][Full Text] [Related]
16. Remoxipride in schizophrenia. A preliminary report.
den Boer JA; Verhoeven WM; Westenberg HG
Acta Psychiatr Scand; 1986 Oct; 74(4):409-14. PubMed ID: 2880457
[TBL] [Abstract][Full Text] [Related]
17. Risperidone for severe tardive dyskinesia: a 12-week randomized, double-blind, placebo-controlled study.
Bai YM; Yu SC; Lin CC
J Clin Psychiatry; 2003 Nov; 64(11):1342-8. PubMed ID: 14658949
[TBL] [Abstract][Full Text] [Related]
18. A double-blind comparative multicentre study of remoxipride and haloperidol in schizophrenia.
Lindström LH; Wieselgren IM; Struwe G; Kristjansson E; Akselson S; Arthur H; Andersen T; Lindgren S; Norman O; Naimell L
Acta Psychiatr Scand Suppl; 1990; 358():130-5. PubMed ID: 1978472
[TBL] [Abstract][Full Text] [Related]
19. A placebo-controlled clinical trial of remoxipride and chlorpromazine in newly admitted schizophrenic patients with acute exacerbation.
Chouinard G
Acta Psychiatr Scand Suppl; 1990; 358():111-9. PubMed ID: 1978469
[TBL] [Abstract][Full Text] [Related]
20. Double blind comparative study of remoxipride and haloperidol in acute schizophrenic patients.
Den Boer JA; Ravelli DP; Huisman J; Ohrvik J; Verhoeven WM; Westenberg HG
Psychopharmacology (Berl); 1990; 102(1):76-84. PubMed ID: 1975448
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
